Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;41(4):1053-1062.
doi: 10.1002/hed.25543. Epub 2018 Dec 14.

Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000

Sarah Schimansky  1 , Samantha Lang  1 , Rhona Beynon  2 , Christopher Penfold  1 , Amy Davies  1 , Andrea Waylen  3 , Steve Thomas  3 , Miranda Pring  3 , Michael Pawlita  4 , Tim Waterboer  5 , Andy Ness  1
Affiliations

Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000

Sarah Schimansky et al. Head Neck. 2019 Apr.

Abstract

Background: People with head and neck cancer have higher comorbidity levels but it remains unclear if pretreatment comorbidity is an independent prognosticator in head and neck cancer.

Methods: Survival analyses were performed using data from participants in a UK multicentre cohort study with cancers of the oral cavity (n = 668), oropharynx (n = 1074), and larynx (n = 530). Survival analyses were incrementally adjusted for age, sex, marital status, income, education, stage, alcohol, and smoking.

Results: After adjusting for demographic, clinical, and behavioral confounders, higher baseline comorbidity was associated with reduced overall survival (mild comorbidity HR = 1.4, 95% CI = 1.1, 1.7; moderate comorbidity HR = 1.7, 95% CI = 1.3, 2.2; severe comorbidity HR = 2.8, 95% CI = 1.9, 4.; P-trend<.001).

Conclusions: Our findings suggest that comorbidity is an independent prognosticator for overall survival in head and neck cancer. Comorbid illnesses should be considered in the assessment and treatment planning of people with head and neck cancer.

Keywords: ACE 27; comorbidity; head and neck cancer; human papillomavirus; survival.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None declared

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592. - PubMed
    1. Pulte D, Brenner H. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. The Oncologist. 2010;15(9):994–1001. - PMC - PubMed
    1. Paleri V, Wight RG, Silver CE, et al. Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice. Oral Oncol. 2010;46(10):712–719. - PubMed
    1. Habbous S, Harland LTG, La Delfa A, et al. Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status. Head Neck. 2014;36(6):802–810. - PubMed
    1. Piccirillo JF. Importance of Comorbidity in Head and Neck Cancer. Laryngoscope. 2000;110(4):593–602. - PubMed

Publication types

MeSH terms